Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta‐analysis
Referencias
Additional references
Auerbach M. Should intravenous iron be the standard of care in oncology?. Journal of Clinical Oncology 2008;26(10):1579‐81.
Barrett‐Lee PJ, Ludwig H, Birgegard G, Bokemeyer C, Gascon P, Kosmidis PA, et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 2006;70(1):34‐48.
Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy‐induced anemia. Journal of Clinical Oncology 2008;26(10):1611‐8.
Bellet RE, Ghazal H, Flam M, Drelichman A, Gabrail N, Woytowitz D, et al. A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. Journal of Clinical Oncology. 2007; Vol. 25, issue 18S:9109.
Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer‐associated anemia. JAMA 2008;299(8):914‐24.
Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta‐analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute 2006;98(10):708‐14.
Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. European Journal of Cancer 2007;43(2):258‐70.
Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683‐91. [PUBMED: 9250266]
Chertow GM, Mason PD, Vaage‐Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. European Dialysis and Transplant Association ‐ European Renal Association 2004;19(6):1571‐5.
Chertow GM, Mason PD, Vaage‐Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. European Dialysis and Transplant Association ‐ European Renal Association 2006;21(2):378‐82.
Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Medical Decision Making 2013;33(5):641‐56. [PUBMED: 23804508]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. [PUBMED: 9310563]
Eschbach JW. Iron requirements in erythropoietin therapy. Best Practice & Research Clinical Haematology 2005;18(2):347‐61.
Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran‐related adverse drug events in hemodialysis patients. American Journal of Kidney Diseases 2001;37(4):743‐9.
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7‐10. [PUBMED: 16360555]
Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo‐controlled, double‐blind trial. Archives of Internal Medicine 1995;155(19):2069‐74. [PUBMED: 7575066]
Mc Master University. GRADEpro. Version 3.2 for Windows. Hamilton, Ontario, Canada: Mc Master University, 2014.
Groopman JE, Itri LM. Chemotherapy‐induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute 1999;91(19):1616‐34. [PUBMED: 10511589]
Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21(4):627‐32.
Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011.
Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011.
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011.
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER Cancer Statistics Review, 1975‐2010. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/ based on November 2012 SEER data submission, posted to the SEER web site, updated December 17, 2014, assessed 03 January 2015.
Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Archives of Internal Medicine 2008;168(21):2377‐81.
Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. American Journal of Medicine 2004;116 Suppl 7A:11S‐26S. [PUBMED: 15050883]
Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta‐analyses. BMC Medical Research Methodology 2013;13:35. [PUBMED: 23496991]
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011.
Link H, Schmitz S. Treatment of cancer‐associated anaemia: results from a two‐day cross‐sectional survey in Germany. Onkologie 2013;36(5):266‐72. [PUBMED: 23689221]
Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology 2001;19(11):2865‐74.
Ludwig H, Strasser K. Symptomatology of anemia. Seminars in Oncology 2001;28(2 Suppl 8):7‐14.
Ludwig H, Van Belle S, Barrett‐Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer 2004;40(15):2293‐306. [PUBMED: 15454256]
Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for iron‐deficiency anemia in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 2002;34(3):286‐90.
Mancuso A, Migliorino M, De Santis S, Saponiero A, De Marinis F. Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Annals of Oncology 2006;17(1):146‐50.
Mercadante S, Ferrera P, Villari P, David F, Giarratano A, Riina S. Effects of red blood cell transfusion on anemia‐related symptoms in patients with cancer. Journal of Palliative Medicine 2009;12(1):60‐3.
Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B. The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving erythropoiesis‐stimulating agents. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD009624.pub2]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006‐12.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Cancer and treatment‐related anemia. NCCN: Clinical Practice Guidelines in Oncology (accessed 20th September 2016).
Rücker G, Schwarzer G, Krahn U, König J. netmeta: Network Meta‐Analysis using Frequentist Methods. R package version 0.9‐0. http://CRAN.R‐project.org/package=netmeta, 2016.
Nissenson AR. Epoetin and cognitive function. American Journal of Kidney Diseases 1992;20(1 Suppl 1):21‐4.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.
Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy‐related anemia without iron deficiency treated with darbepoetin alpha. Journal of Clinical Oncology 2008;26(10):1619‐25.
Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello‐Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta‐analysis. BMJ (Clinical research ed.) 2014;349:g5630. [PUBMED: 25252733]
R Core Team. R: A language and environment for statistical computing. Version 3.1.0. Vienna, Austria: R Foundation for Statistical Computing, 2014.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Journal of Clinical Oncology 2010;28(33):4996‐5010.
Rodgers GM, 3rd, Becker PS, Blinder M, Cella D, Chanan‐Khan A, Cleeland C, et al. Cancer‐ and chemotherapy‐induced anemia. Journal of the National Comprehensive Cancer Network 2012;10(5):628‐53.
Rücker G. Network meta‐analysis, electrical networks and graph theory. Research Synthesis Methods 2012;3(4):312‐24. [PUBMED: 26053424]
Rücker G, Schwarzer G. Reduce dimension or reduce weights? Comparing two approaches to multi‐arm studies in network meta‐analysis. Statistics in Medicine 2014;33(25):4353‐69. [PUBMED: 24942211]
Rücker G, Schwarzer G. Ranking treatments in frequentist network meta‐analysis works without resampling methods. BMC Medical Research Methodology 2015;15:58. [PUBMED: 26227148]
Schrijvers D, De Samblanx H, Roila F. Erythropoiesis‐stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Annals of Oncology 2010;21 Suppl 5:244‐7.
Schuenemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings tables'. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011.
Schwarzer G, Carpenter JR, Rücker G. Chapter 8: Network meta‐analysis. Meta‐Analysis with R. Springer International Publishing Switzerland, 2015.
Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancer‐related fatigue: evolving concepts in evaluation and treatment. Cancer 2003;98(9):1786‐801.
Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy‐associated anemia. Journal of Clinical Oncology 2011;29(1):97‐105.
Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. The Cochrane Collaboration, 2011.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16. [PUBMED: 17555582]
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD003407.pub5; PUBMED: 23235597]
Wang C, Graham DJ, Kane RC, Xie D, Wernecke M, Levenson M, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015;314(19):2062‐8. [PUBMED: 26575062]
